Bioequivalence Study of Ulipristal Acetate 30 mg Tablets in Healthy Volunteers Under Fed Conditions

The primary objective of this study is to evaluate the **bioequivalence** of Ulipristal 30 mg tablets in healthy subjects under fed conditions. Bioequivalence studies are crucial in determining whether two pharmaceutical products are equivalent in terms of their bioavailability, which is essential for ensuring therapeutic equivalence. This is particularly important for medications like Ulipristal, which is used for emergency contraception, as consistent bioavailability ensures reliable efficacy and safety for users. There are no secondary objectives listed for this study.

The clinical trial involves a **study population** consisting exclusively of female participants, with an age range categorized as adults. The trial does not focus on any specific **medical condition**, indicating that participants are generally healthy. The sponsor has not provided information regarding the total number of participants involved in the study. The trial population was selected with consideration for vulnerable populations, although specific lifestyle factors such as diet, physical activity, or habits have not been detailed. The absence of a defined medical condition suggests a broad inclusion of healthy individuals, with no significant exclusion criteria explicitly mentioned. The sponsor has not disclosed the main objective of the trial.

The clinical trial is designed to evaluate the **bioequivalence** of Ulipristal 30 mg tablets in healthy subjects under fed conditions. This study is a Phase 2 trial, which is categorized as a bioequivalence study. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from August 18, 2023, to June 18, 2024, encompassing both the recruitment and study phases.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized and proceed to the treatment phase, where they will receive the investigational product under controlled conditions. Throughout the trial, follow-up visits will be scheduled to monitor the participants' health status and collect necessary data for the study endpoints. The trial will conclude with an end-of-study visit, during which final assessments will be conducted to evaluate the outcomes of the intervention.

The expected length of participant involvement in the study is approximately 10 months, aligning with the overall trial duration. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with study protocols, or withdraw consent. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatment protocols accurately.

The clinical trial is in Phase 2 and is scheduled to have an estimated recruitment start date of August 18, 2023, with an estimated end date of June 18, 2024. Efficacy assessment details, including specific parameters or endpoints, methods, and tools for measuring efficacy, are not provided in the available data. The trial's primary and secondary endpoints, as well as the main objective, are not specified. Consequently, the description of efficacy assessment cannot include these elements. The trial is categorized under trial category 1, with a trial category ID of 21691.